News and Trends 17 Apr 2015
Teva took the first step to get the approval of its new leukemia treatment
FDA accepted Teva Pharma’s New Drug Application (NDA) for a liquid bendamustine hydrochloride (HCl) rapid infusion product. The drug, developed with Eagle Pharmaceuticals is now waiting for the Prescription Drug User Fee Act (PDUFA), which is expected for December 2015. In the meantime, the Israeli company remains unstoppable after a great begining of the month on […]
